

FOR IMMEDIATE RELEASE

ULTRAGREEN.AI SECURES REGULATORY APPROVAL FOR VERDYE IN SINGAPORE, ADVANCING SOUTHEAST ASIA EXPANSION

Approval in a strategic healthcare hub strengthens regional growth strategy and supports clinical adoption of fluorescence-guided surgery

Singapore, 5 May 2026 — UltraGreen.ai Limited (SGX: ULG) (“UltraGreen.ai” or the “Company”), a global leader in fluorescence-guided surgery and digital health solutions, today announced regulatory approval for Verdye (indocyanine green for injection) in Singapore.

This approval represents a strategic step in the Company’s Southeast Asia growth strategy, expanding its addressable market and strengthening its presence in a key regional healthcare hub.

Singapore plays a critical role as a centre for clinical excellence and regional influence, supporting broader adoption of advanced surgical technologies across Southeast Asia.

This approval enables UltraGreen.ai to advance commercialisation efforts, deepen partnerships with leading healthcare institutions, and support clinical adoption of fluorescence-guided surgery.

Fluorescence-guided surgery using ICG is now widely adopted across multiple surgical specialties, including oncology, colorectal, reconstructive, and vascular procedures. Verdye’s entry into Singapore enhances access to a globally established product with a strong track record across international markets.

Scaling an Integrated Fluorescence-Guided Surgery Platform

UltraGreen.ai’s approach extends beyond individual product approvals. The Company continues to build a comprehensive fluorescence-guided surgery ecosystem, combining pharmaceutical products, compatible imaging hardware, and AI-powered data platforms designed to support surgical decision-making, standardisation and improved patient outcomes.

It further strengthens the Company’s ability to scale this platform regionally, supporting long-term growth through increased procedural adoption and recurring product utilisation.

Commenting on the approval, Ravi Sajwan, Chief Executive Officer of UltraGreen.ai, said:

“Singapore is a strategically important market for UltraGreen.ai — not only for its world-class healthcare system, but also for its role as a regional reference point for clinical adoption across Southeast Asia. This approval reinforces our strong regulatory execution and clear momentum in our regional strategy. We are well positioned to support surgeons with proven fluorescence-guided solutions while laying the groundwork for continued growth and innovation across Southeast Asia.”

This latest milestone builds on UltraGreen.ai’s recent IPO and regulatory approval of Verdyne in the Philippines, underscoring strong execution and the Company’s long-term commitment to advancing precision surgery through high-quality pharmaceutical, imaging, and data-driven solutions. Verdyne is now approved in 41 countries globally, with the IC-Flow™ imaging system cleared in 45 markets, reflecting the Company’s expanding international footprint and ability to scale its integrated fluorescence-guided surgery platform.

About UltraGreen.ai

UltraGreen.ai Limited (SGX: ULG) is a global leader in fluorescence-guided surgery, pioneering vertical AI tools for precision surgery through data-driven fluorescence imaging solutions. The Company’s flagship Indocyanine Green (“ICG”) product — marketed as IC-GREEN® in the United States, Indocyanine Green for Injection, USP in the United States and Canada, and Verdyne outside North America — is the most widely used fluorescence imaging agent globally.

UltraGreen offers an integrated fluorescence imaging ecosystem that empowers surgeons with enhanced visualisation and real-time perfusion insights, supporting greater surgical precision and improved patient outcomes. Headquartered in Singapore, UltraGreen operates globally, with a strong presence in the United States and Ireland, as well as offices across Asia-Pacific.

For more information, visit www.ultragreen.ai

Media Contact

H/Advisors Klareco

Klareco-Ultragreen@h-advisors.global